153. Acute encephalitis with refractory repetitive partial seizures Disease details / Clinical trials / Drug dev / DR info /
Clinical trials : 3 / Drugs : 3 - (DrugBank : 2) / Drug target genes : 3 - Drug target pathways : 22
Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)
Anakinra
Beijing Childrens Hospital,Capital Medical University
2026 - ChiCTR2600126257 China
Yale University
2026 Phase 3 NCT07281027 Canada;France;Italy;South Korea;Sweden;United Kingdom;United States
Standard medical treatment
Yale University
2026 Phase 3 NCT07281027 Canada;France;Italy;South Korea;Sweden;United Kingdom;United States
Tocilizumab
Beijing Childrens Hospital,Capital Medical University
2026 - ChiCTR2600126257 China
Peking University First Hospital
2024 Phase 4 ChiCTR2400085185 China
Yale University
2026 Phase 3 NCT07281027 Canada;France;Italy;South Korea;Sweden;United Kingdom;United States
Beijing Childrens Hospital,Capital Medical University
2026 - ChiCTR2600126257 China
Yale University
2026 Phase 3 NCT07281027 Canada;France;Italy;South Korea;Sweden;United Kingdom;United States
Standard medical treatment
Yale University
2026 Phase 3 NCT07281027 Canada;France;Italy;South Korea;Sweden;United Kingdom;United States
Tocilizumab
Beijing Childrens Hospital,Capital Medical University
2026 - ChiCTR2600126257 China
Peking University First Hospital
2024 Phase 4 ChiCTR2400085185 China
Yale University
2026 Phase 3 NCT07281027 Canada;France;Italy;South Korea;Sweden;United Kingdom;United States
